Literature DB >> 11937008

Combination chemotherapy for ovarian cancer--lessons not yet learned?

Stanley B Kaye1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11937008     DOI: 10.1007/s11912-002-0013-3

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  2 in total

1.  Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

Authors:  F M Muggia; P S Braly; M F Brady; G Sutton; T H Niemann; S L Lentz; R D Alvarez; P R Kucera; J M Small
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

Review 2.  Chemotherapy for advanced ovarian cancer: overview of randomized trials.

Authors:  J T Thigpen
Journal:  Semin Oncol       Date:  2000-06       Impact factor: 4.929

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.